About
Titles
Statistician 3
Appointments
Departments & Organizations
Research
Research at a Glance
Yale Co-Authors
Frequent collaborators of Yu Yamamoto's published research.
Publications Timeline
A big-picture view of Yu Yamamoto's research output by year.
F. Perry Wilson, MD, MSCE
Dennis G Moledina, MD, PhD, FASN
Michael Simonov, MD
Tariq Ahmad, MD, MPH
Chirag Parikh, MD, PhD, FACP
Jason Greenberg, MD, MHS
8Publications
14Citations
Publications
2024
Promoting Collaborative Scholarship During the COVID-19 Pandemic Through an Innovative COVID-19 Data Explorer and Repository at Yale School of Medicine: Development and Usability Study
Victoria-Castro A, Arora T, Simonov M, Biswas A, Alausa J, Subair L, Gerber B, Nguyen A, Hsiao A, Hintz R, Yamamoto Y, Soufer R, Desir G, Wilson F, Villanueva M. Promoting Collaborative Scholarship During the COVID-19 Pandemic Through an Innovative COVID-19 Data Explorer and Repository at Yale School of Medicine: Development and Usability Study. JMIR Formative Research 2024, 8: e52120. PMID: 39226547, PMCID: PMC11408881, DOI: 10.2196/52120.Peer-Reviewed Original ResearchAltmetricPragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial
Shah N, Ghazi L, Yamamoto Y, Kumar S, Martin M, Simonov M, Riello Iii R, Faridi K, Ahmad T, Wilson F, Desai N. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial. Circulation Cardiovascular Quality And Outcomes 2024, 17: e010335. PMID: 38634282, DOI: 10.1161/circoutcomes.123.010335.Peer-Reviewed Original ResearchCitationsAltmetricConceptsElectronic health recordsElectronic health record alertsHigh-risk atherosclerotic cardiovascular diseaseLipid lowering therapyAtherosclerotic cardiovascular diseasePragmatic trialCardiovascular diseaseProportion of patientsYale New Haven HealthLDL-CSecondary outcomesPrimary outcomeInternal medicine cliniciansEHR alertUsual careHealth recordsProvider levelCluster-randomizedLDL-C managementLDL-C levelsAdverse cardiovascular eventsRandomized clinical trialsTreatment of hyperlipidemiaCliniciansCardiovascular eventsCOVID-19−Associated Acute Kidney Injury and Longitudinal Kidney Outcomes
Aklilu A, Kumar S, Nugent J, Yamamoto Y, Coronel-Moreno C, Kadhim B, Faulkner S, O’Connor K, Yasmin F, Greenberg J, Moledina D, Testani J, Wilson F. COVID-19−Associated Acute Kidney Injury and Longitudinal Kidney Outcomes. JAMA Internal Medicine 2024, 184: 414-423. PMID: 38407862, PMCID: PMC10897825, DOI: 10.1001/jamainternmed.2023.8225.Peer-Reviewed Original ResearchCitationsAltmetricConceptsCOVID-19-associated acute kidney injuryCOVID-19-associated AKIAcute kidney injuryMulticenter cohort studyKidney function declineKidney functionKidney injuryCohort studyKidney outcomes of patientsIncidence of acute kidney injuryLong-term kidney outcomesHistorical cohort of patientsMultivariate time-to-event analysesPositive influenza ALongitudinal multicenter cohort studyWorsening kidney functionOutcomes of patientsAdverse kidney eventsCohort of patientsComposite of mortalityMarkers of illness severityAdult hospitalized patientsBaseline comorbidity scoreTime-to-event analysisFunctional declineELECTRONIC ALERTS TO IMPROVE MINERALOCORTICOID RECEPTOR ANTAGONIST USE AND HYPERKALEMIA MANAGEMENT IN AMBULATORY PATIENTS WITH HEART FAILURE: A CLUSTER RANDOMIZED TRIAL
Clark K, Victoria-Castro A, Ghazi, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. ELECTRONIC ALERTS TO IMPROVE MINERALOCORTICOID RECEPTOR ANTAGONIST USE AND HYPERKALEMIA MANAGEMENT IN AMBULATORY PATIENTS WITH HEART FAILURE: A CLUSTER RANDOMIZED TRIAL. Journal Of The American College Of Cardiology 2024, 83: 2395. DOI: 10.1016/s0735-1097(24)04385-7.Peer-Reviewed Original Research
2023
Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF
O’Connor K, Yamamoto Y, Sen S, Samsky M, Wilson F, Desai N, Ahmad T, Fuery M. Risk Prediction for Heart Failure Patients Admitted to the Intensive Care Unit Insights From REVeAL-HF. JACC Heart Failure 2023, 11: 727-728. PMID: 37052546, DOI: 10.1016/j.jchf.2023.01.021.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
2021
Prognostic Significance of Urinary Biomarkers in Patients Hospitalized with COVID-19
Menez S, Moledina D, Philbrook H, Wilson F, Obeid W, Simonov M, Yamamoto Y, villalobos C, Chang C, Garibaldi B, Clarke W, Farhadian S, Dela Cruz C, Coca S, Parikh C. Prognostic Significance of Urinary Biomarkers in Patients Hospitalized with COVID-19. Journal Of The American Society Of Nephrology 2021, 32: 107-107. DOI: 10.1681/asn.20213210s1107a.Peer-Reviewed Original ResearchAKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy
Baker M, Yamamoto Y, Perazella M, Parikh C, Wilson F, Moledina D. AKI and Mortality in Patients Prescribed Immune Checkpoint Inhibitor Therapy. Journal Of The American Society Of Nephrology 2021, 32: 132-132. DOI: 10.1681/asn.20213210s1132c.Peer-Reviewed Original Research
2020
Electronic Health Record Alerts for AKI: A MultiCenter Randomized Clinical Trial
Wilson F, Martin M, Yamamoto Y, Feldman H, Greenberg J, Mansour S, Moledina D, Palevsky P, Parikh C, Simonov M. Electronic Health Record Alerts for AKI: A MultiCenter Randomized Clinical Trial. Journal Of The American Society Of Nephrology 2020, 31: b3-b3. DOI: 10.1681/asn.20203110s1b3c.Peer-Reviewed Original Research
News
News
- October 25, 2024
Can a ‘Kidney Action Team’ Improve Patient Outcomes?
- September 24, 2024
Yale Database DOM-CovX Streamlines Research Process, Fosters Collaboration
- February 26, 2024
Reanalyzing the Impact of COVID-19 on the Kidneys
- May 25, 2023
Internal Medicine Staff Celebrated for Service Anniversaries
Get In Touch
Contacts
Email